Beschreibung
The objective of the present study was directed towards developing a colon specific drug delivery system of aceclofenac, the non-steroidal anti-inflammatory drug associated with circadian rhythm of chronobiological symptoms for effective management of rheumatoid arthritis. Aceclofenac is a cox 2 selective inhibitor and has better safety than conventionalnon-steroidal anti-inflammatory drugs with respect to adverse effects on gastrointestinal and cardiovascular system. Aceclofenac is rapidly and completely absorbed after oral administration. Peak plasma concentration reaches in 1-3 h after an oral dose. The plasma elimination half life of the drug is approximately 4 h. The chronopharmacological approach for the management of rheumatoid arthritis has been well documented. Considering this factor, aceclofenac under investigation in the present study was developed as a colon targeted delivery system through tablets, pellets and microspheres. Additionally a Pulsincap drug delivery of the drug was also studied to meet the objective of circadian rhythm in rheumatoid arthritis.
Autorenporträt
Dr. S.K. UMA DEVI has completed M.Pharmacy and Ph.D. in pharmaceutical sciences from the Tamil Nadu DR.M.G.R. Medical University and research institute. Presently working as Professor and Principal in ST. PAULS COLLEGE OF PHARMACY, OSMANIA UNIVERSITY, and HYDERABAD, INDIA.
Herstellerkennzeichnung:
OmniScriptum SRL
Str. Armeneasca 28/1, office 1
2012 Chisinau
MD
E-Mail: info@omniscriptum.com
